Table 5.
Susceptibilities of BMS-626529-resistant clinical samples to other entry inhibitors
| Subject (clone) | Tropism | BMS-626529 resistance substitution(s) | Mean fold change in EC50 ± SDa |
Mean EC50 (nM) ± SD of MVCa | ||
|---|---|---|---|---|---|---|
| BMS-626529 | ENF | Ibalizumab | ||||
| 16 (1) | CCR5 | M426L/M475I | 2,932 ± 404 | 4.2 ± 2.3 | 0.6 ± 0.1 | 7.4 ± 1.3 |
| 21 (170) | CCR5 | M426L | 386 ± 95 | 13.4 ± 2.8 | 1.6 ± 0.9 | 9.2 ± 1.8 |
| 21 (169) | CXCR4 | M426L | 215 ± 76 | 1.9 ± 0.6 | 0.5 ± 0.1 | >5,000 |
| 41 (33) | CCR5 | S375M/M434I | >19,418 | 1.5 ± 0.3 | 0.7 ± 0.1 | 4.0 ± 0.1 |
a
Mean values of two independent experiments.